Non-ATP competitive glycogen synthase kinase 3β (GSK-3β) inhibitors: Study of structural requirements for thiadiazolidinone derivatives
Ana Castro(Instituto de Química Médica), Ana Martı́nez(Consejo Superior de Investigaciones Científicas), Carmen Gil(Instituto de Salud Carlos III), Francisco J. Moreno(Instituto de Química Médica), Concepción Pérez(Instituto de Química Médica), Williams Porcal(Instituto de Química Médica), Stefan Bräse(Karlsruhe Institute of Technology), Arantxa Encinas(Instituto de Química Médica)
Cited by 57
Related Papers
COVID-19: Drug Targets and Potential Treatments
|Journal of Medicinal Chemistry|2020|469
First Non-ATP Competitive Glycogen Synthase Kinase 3 β (GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease
|Journal of Medicinal Chemistry|2002|448
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS
|Frontiers in Molecular Neuroscience|2011|348
Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation
|Medicinal Research Reviews|2002|334
TNFα disrupts blood brain barrier integrity to maintain prolonged depressive-like behavior in mice
|Brain Behavior and Immunity|2018|293